Ioannis Xefteris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ioannis Xefteris has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Argyrios Periferakis
Faculty of Medicine, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
3 shared publications - Andreea-Elena Scheau
Department of Radiology and Medical Imaging, “Foisor” Clinical Hospital of Orthopaedics, Traumatology and Osteoarticular TB, 021382 Bucharest, Romania
2 shared publications - Aristodemos-Theodoros Periferakis
Faculty of Medicine, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
2 shared publications - Cristian Scheau
The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
2 shared publications - Konstantinos Periferakis
Akadimia of Ancient Greek and Traditional Chinese Medicine, 16675 Athens, Greece
2 shared publications - Lamprini Troumpata
Faculty of Medicine, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
2 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (5) , 1110
Infectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges
Spinal infections in general, and infectious spondylodiscitis in particular, are increasingly diagnosed in the Western world, in recent decades. This rise in incidence is associated with an ageing population and with an increased availability of accurate diagnostic modalities. Even so, due to the non-specific nature of clinical manifestations, and of the implicated blood and serum markers, there is a risk of underdiagnosis or misdiagnosis of the disease in its initial stages. Ionizing radiation methods, such as plain radiography (X-ray) and computed tomography (CT), are also not reliable in the early stages of the diseases, and the golden standard of imagistic diagnosis, magnetic resonance imaging (MRI), is not always available or requested. Still, MRI remains the most reliable method in most cases where there is a need for differential diagnosis with other pathologies, namely Andersson lesions, destructive spondyloarthropathy, erosive osteochondritis, micro-crystalline spondylitis, Modic 1 lesion, Charcot spinal arthropathy, osteoporotic fractures, SAPHO syndrome with spinal involvement, and Schmorl’s nodes. Infectious spondylodiscitis is caused by bacteria, and, less frequently, by fungi. Rare cases of parasitic causes have also been reported in the literature. Infectious spondylodiscitis of bacterial causes may be pyogenic, more frequently caused by Staphylococcus spp. or Streptococcus spp., or granulomatous, usually caused by Mycobacterium tuberculosis complex (MTBC) or from classical brucellosis. In all these cases, therapy may be conservative, with antibiotics, or surgical, when the former fails or in patients with significant spinal instability or other neurological manifestations. There are various surgical approaches, each with its own drawbacks, and usually used according to the preference of the attending physician. Even in cases of surgical treatment, antibiotic administration is prolonged, and it is important for a proper scheme to be selected based on antimicrobial susceptibility testing. However, given that in many cases, the causative agent cannot be identified, empirical treatment must be initiated. Finally, newer approaches, including the incorporation of antimicrobial substances, may offer better solutions for improving treatment and rehabilitation outcomes.
- 13 May 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (5) , 1110
Open AccessInfectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges
Spinal infections in general, and infectious spondylodiscitis in particular, are increasingly diagnosed in the Western world, in recent decades. This rise in incidence is associated with an ageing population and with an increased availability of accurate diagnostic modalities. Even so, due to the non-specific nature of clinical manifestations, and of the implicated blood and serum markers, there is a risk of underdiagnosis or misdiagnosis of the disease in its initial stages. Ionizing radiation methods, such as plain radiography (X-ray) and computed tomography (CT), are also not reliable in the early stages of the diseases, and the golden standard of imagistic diagnosis, magnetic resonance imaging (MRI), is not always available or requested. Still, MRI remains the most reliable method in most cases where there is a need for differential diagnosis with other pathologies, namely Andersson lesions, destructive spondyloarthropathy, erosive osteochondritis, micro-crystalline spondylitis, Modic 1 lesion, Charcot spinal arthropathy, osteoporotic fractures, SAPHO syndrome with spinal involvement, and Schmorl’s nodes. Infectious spondylodiscitis is caused by bacteria, and, less frequently, by fungi. Rare cases of parasitic causes have also been reported in the literature. Infectious spondylodiscitis of bacterial causes may be pyogenic, more frequently caused by Staphylococcus spp. or Streptococcus spp., or granulomatous, usually caused by Mycobacterium tuberculosis complex (MTBC) or from classical brucellosis. In all these cases, therapy may be conservative, with antibiotics, or surgical, when the former fails or in patients with significant spinal instability or other neurological manifestations. There are various surgical approaches, each with its own drawbacks, and usually used according to the preference of the attending physician. Even in cases of surgical treatment, antibiotic administration is prolonged, and it is important for a proper scheme to be selected based on antimicrobial susceptibility testing. However, given that in many cases, the causative agent cannot be identified, empirical treatment must be initiated. Finally, newer approaches, including the incorporation of antimicrobial substances, may offer better solutions for improving treatment and rehabilitation outcomes.
- Open Access
- 25 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3816
Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions
Somatostatin is a potent endocrine regulator and neurotransmitter, exerting predominantly inhibitory effects in different tissues of the body, via G-protein coupled receptors. Five such specific receptors have been identified, with different effects and tissue distribution. The multifaceted actions and effects of somatostatin make it useful as a potential therapeutical means in various pathologies; however, in clinical practice, somatostatin analogues, namely octreotide, lanreotide and pasireotide, are commonly used instead, due to their increased half-life and increased receptor selectivity, with pasireotide showing a more extensive receptor binding profile and high affinity for somatotastin receptor (SSTR) 5, which may prove effective in cases of resistance to first-generation analogues. Apart from their many uses in neoplastic pathologies, somatostatin analogues represent viable treatment choices in some ocular pathologies, congenital hyperinsulinism, gastrointestinal bleedings and portal hypertension, acute pancreatitis, and dumping syndrome. They have also been used in some cases, with varying degrees of success, in patients with post-surgical gastrointestinal and lymphatic fistulas, refractory chronic diarrhoea and polycystic kidney disease; many applications in paediatric patients have also been documented. The aim of this review is to present the applications of somatostatin and its analogues as alternative or second-line therapies, along with insights into their effectiveness and future potential.
- 25 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3816
Open AccessSomatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions
Somatostatin is a potent endocrine regulator and neurotransmitter, exerting predominantly inhibitory effects in different tissues of the body, via G-protein coupled receptors. Five such specific receptors have been identified, with different effects and tissue distribution. The multifaceted actions and effects of somatostatin make it useful as a potential therapeutical means in various pathologies; however, in clinical practice, somatostatin analogues, namely octreotide, lanreotide and pasireotide, are commonly used instead, due to their increased half-life and increased receptor selectivity, with pasireotide showing a more extensive receptor binding profile and high affinity for somatotastin receptor (SSTR) 5, which may prove effective in cases of resistance to first-generation analogues. Apart from their many uses in neoplastic pathologies, somatostatin analogues represent viable treatment choices in some ocular pathologies, congenital hyperinsulinism, gastrointestinal bleedings and portal hypertension, acute pancreatitis, and dumping syndrome. They have also been used in some cases, with varying degrees of success, in patients with post-surgical gastrointestinal and lymphatic fistulas, refractory chronic diarrhoea and polycystic kidney disease; many applications in paediatric patients have also been documented. The aim of this review is to present the applications of somatostatin and its analogues as alternative or second-line therapies, along with insights into their effectiveness and future potential.
- Open Access
- 17 September 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e949359
Constipation as an Atypical Presentation of Hyperparathyroidism: A Case Report
BACKGROUND Hyperparathyroidism is a relatively rare endocrine disorder, albeit with increasing prevalence in the last years. While oftentimes clinically silent, it can lead to severe hypercalcemia, which is life-threatening and a medical emergency. Therefore, prompt diagnosis and treatment are essential, even in cases presenting with atypical symptoms. CASE REPORT We present a case of a patient with hyperparathyroidism presenting in the Emergency Department with only gastrointestinal symptoms. A 77-year-old woman presented with progressively more severe constipation and involuntary weight loss in the past 3 months. A computed tomography scan revealed calcified and non-calcified plaques in the lumen of the celiac trunk and superior mesenteric artery, along with diffusely distributed microcalcifications of the liver parenchyma. Colonoscopy could not be performed, due to increased and intractable fecal loading. After a laboratory examination revealed normochromic normocytic anemia and elevated ferritin and creatinine, further tests were ordered, and severe hypercalcemia, with serum calcium levels over 15 mg/dL, and parathormone levels over 1000 pg/mL were detected. Therefore, the diagnosis of primary hyperparathyroidism was established, attributed to a parathyroid gland adenoma visualized on computed tomography. The patient was subsequently referred to the Endocrinology Department. CONCLUSIONS With clinical awareness, patients presenting with unexplained gastrointestinal symptoms can be screened for and receive a diagnosis of hyperparathyroidism, by a prompt laboratory checkup of calcium and parathormone levels.
- 17 September 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e949359
Open AccessConstipation as an Atypical Presentation of Hyperparathyroidism: A Case Report
BACKGROUND Hyperparathyroidism is a relatively rare endocrine disorder, albeit with increasing prevalence in the last years. While oftentimes clinically silent, it can lead to severe hypercalcemia, which is life-threatening and a medical emergency. Therefore, prompt diagnosis and treatment are essential, even in cases presenting with atypical symptoms. CASE REPORT We present a case of a patient with hyperparathyroidism presenting in the Emergency Department with only gastrointestinal symptoms. A 77-year-old woman presented with progressively more severe constipation and involuntary weight loss in the past 3 months. A computed tomography scan revealed calcified and non-calcified plaques in the lumen of the celiac trunk and superior mesenteric artery, along with diffusely distributed microcalcifications of the liver parenchyma. Colonoscopy could not be performed, due to increased and intractable fecal loading. After a laboratory examination revealed normochromic normocytic anemia and elevated ferritin and creatinine, further tests were ordered, and severe hypercalcemia, with serum calcium levels over 15 mg/dL, and parathormone levels over 1000 pg/mL were detected. Therefore, the diagnosis of primary hyperparathyroidism was established, attributed to a parathyroid gland adenoma visualized on computed tomography. The patient was subsequently referred to the Endocrinology Department. CONCLUSIONS With clinical awareness, patients presenting with unexplained gastrointestinal symptoms can be screened for and receive a diagnosis of hyperparathyroidism, by a prompt laboratory checkup of calcium and parathormone levels.